Recent advances in managing and understanding nephrolithiasis/nephrocalcinosis
暂无分享,去创建一个
[1] R. Abe,et al. RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2020, The journal of allergy and clinical immunology. In practice.
[2] T. Nomura,et al. Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. , 2019, The journal of allergy and clinical immunology. In practice.
[3] W. Garner,et al. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2019, Burns : journal of the International Society for Burn Injuries.
[4] S. Mallal,et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions , 2019, Nature Communications.
[5] K. Mounzer,et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study , 2019, AIDS Research and Therapy.
[6] D. Kroshinsky,et al. Use of Cyclosporine for the treatment of Steven Johnson Syndrome/ Toxic Epidermal Necrolysis. , 2019, Journal of the American Academy of Dermatology.
[7] L. Scherrer,et al. Efficacy and safety of cyclosporine in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2018, Dermatologic therapy.
[8] F. Wang,et al. Diverse expression of TNF-α and CCL27 in serum and blister of Stevens–Johnson syndrome/toxic epidermal necrolysis , 2018, Clinical and Translational Allergy.
[9] W. Yeo,et al. A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis , 2018, Journal of inflammation research.
[10] T. Harr,et al. Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis , 2018, Clinical Reviews in Allergy & Immunology.
[11] Qi Guo,et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: A prospective observational study , 2017, Journal of critical care.
[12] E. Ramírez,et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. , 2017, The Journal of investigative dermatology.
[13] M. Mockenhaupt,et al. New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.
[14] Kuang-Hui Yu,et al. Diagnostic utility of HLA‐B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta‐analysis , 2017, International journal of rheumatic diseases.
[15] C. Ng,et al. HLA-A*31: 01 and HLA-B*15:02 association with Stevens–Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population , 2017, Pharmacogenetics and genomics.
[16] H. Chuang,et al. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions , 2017, The Journal of Rheumatology.
[17] M. Schumacher,et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis , 2017, JAMA dermatology.
[18] C. Ng,et al. HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions , 2017, Neurology.
[19] M. Schumacher,et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.
[20] Veronika Vidova,et al. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. , 2017, Analytica chimica acta.
[21] Philip R. Cohen,et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures , 2017, Advances in Therapy.
[22] Hyon K. Choi,et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. , 2017, Seminars in arthritis and rheumatism.
[23] Z. Liu,et al. A study of HLA‐B*15:02 in 9 different Chinese ethnics: Implications for carbamazepine related SJS/TEN , 2017, HLA.
[24] T. Kuo,et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians , 2017, Neurology.
[25] Lei Yu,et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies , 2016, Oncotarget.
[26] C. Sukasem,et al. HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand , 2016, Front. Pharmacol..
[27] J. Silverberg,et al. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, Journal of Investigative Dermatology.
[28] W. Chung,et al. Severe cutaneous adverse drug reactions , 2016, The Journal of dermatology.
[29] P. Dziewulski,et al. U.K. guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016 , 2016, The British journal of dermatology.
[30] P. Dziewulski,et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[31] C. Ng,et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population , 2016, The Pharmacogenomics Journal.
[32] G. Gambaro,et al. Role of Osteogenesis in the Formation of Randall's Plaques , 2016, Anatomical record.
[33] H. Park,et al. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs , 2015, Yonsei medical journal.
[34] Wei-Chi Wang,et al. Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. , 2015, The Journal of investigative dermatology.
[35] W. Zhang,et al. HLA‐B*58:01 is strongly associated with allopurinol‐induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case–control clinical study , 2015, The British journal of dermatology.
[36] R. Unwin,et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] G. Gambaro,et al. Spontaneous calcification process in primary renal cells from a medullary sponge kidney patient harbouring a GDNF mutation , 2015, Journal of cellular and molecular medicine.
[38] R. Abe. Immunological response in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2015, The Journal of dermatology.
[39] S. Aronoff,et al. Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta‐analysis with meta‐regression of observational studies , 2015, International journal of dermatology.
[40] A. Papp,et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. , 2014, Journal of the American Academy of Dermatology.
[41] D. Huh,et al. Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. , 2014, American journal of respiratory and critical care medicine.
[42] S. Tsai,et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.
[43] D. Didona,et al. Etanercept therapy for toxic epidermal necrolysis. , 2014, Journal of the American Academy of Dermatology.
[44] F. Wang,et al. Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[45] H. Shimizu,et al. An annexin A1–FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions , 2014, Science Translational Medicine.
[46] M. Nichelatti,et al. Guida Alla Lettura dei Risultati Della Metanalisi Dello Studio: “Medical Management to Prevent Recurrent Nephrolithiasis in Adults: A Systematic Review for an American College of Physicians Clinical Guideline” , 2014 .
[47] V. Scott-Lang,et al. Toxic Epidermal Necrolysis in a Child Successfully Treated with Infliximab , 2014, Pediatric dermatology.
[48] W. Pichler,et al. Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01 , 2014, The Journal of Immunology.
[49] U. Amstutz,et al. Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions , 2014, Epilepsia.
[50] Y. L. Lim,et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre , 2013, The British journal of dermatology.
[51] P. Wolkenstein,et al. French referral center management of Stevens–Johnson syndrome/toxic epidermal necrolysis , 2013 .
[52] M. Gonçalo,et al. HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population , 2013, The British journal of dermatology.
[53] Takashi Sugamori,et al. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. , 2013, Journal of dermatological science.
[54] P. Kwan,et al. HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.
[55] L. Naldi,et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2013, The Journal of investigative dermatology.
[56] G. Gambaro,et al. When to suspect a genetic disorder in a patient with renal stones, and why. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[57] G. Gambaro,et al. Familial clustering of medullary sponge kidney is autosomal dominant with reduced penetrance and variable expressivity. , 2013, Kidney international.
[58] H. Shimizu,et al. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. , 2013, The Journal of allergy and clinical immunology.
[59] Dawn S. Milliner,et al. Hereditary causes of kidney stones and chronic kidney disease , 2013, Pediatric Nephrology.
[60] I. Bassukas,et al. Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient , 2012, Case reports in dermatological medicine.
[61] G. Capasso,et al. Calcium nephrolithiasis, metabolic syndrome and the cardiovascular risk. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[62] Y.-C. Huang,et al. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta‐analysis , 2012, The British journal of dermatology.
[63] H. Shimizu,et al. Prolonged elevation of serum granulysin in drug‐induced hypersensitivity syndrome , 2012, The British journal of dermatology.
[64] Yuan-Tsong Chen,et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. , 2012, The Journal of allergy and clinical immunology.
[65] J. McCluskey,et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.
[66] S. Mallal,et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.
[67] N. Maalouf,et al. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. , 2012, The Journal of clinical endocrinology and metabolism.
[68] G. Gambaro,et al. Dietary habits in women with recurrent idiopathic calcium nephrolithiasis , 2012, Journal of Translational Medicine.
[69] A. Trinchieri. Development of a rapid food screener to assess the potential renal acid load of diet in renal stone formers (LAKE score). , 2012, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[70] K. Sayama,et al. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens–Johnson syndrome and toxic epidermal necrolysis , 2012, The British journal of dermatology.
[71] Yuan-Tsong Chen,et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. , 2011, The Journal of allergy and clinical immunology.
[72] Sang-Heon Cho,et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.
[73] G. Koren,et al. Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children , 2011, Pediatrics.
[74] G. Vezzoli,et al. Genetics and calcium nephrolithiasis. , 2011, Kidney international.
[75] R. Jamal,et al. Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. , 2011, Asian Pacific journal of allergy and immunology.
[76] B. Moser,et al. The Human Cutaneous Chemokine System , 2011, Front. Immun..
[77] Q. Wang,et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland , 2011, Seizure.
[78] J. Roujeau,et al. Systematic review of treatments for Stevens–Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality , 2011, Therapeutic advances in drug safety.
[79] Jacqueline Adam,et al. Delayed drug hypersensitivity: models of T-cell stimulation. , 2011, British journal of clinical pharmacology.
[80] Michael R. Johnson,et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.
[81] Chen-Yang Shen,et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.
[82] Limei Zhao,et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.
[83] T. Shiohara,et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? , 2011, The Journal of dermatology.
[84] Yusuke Nakamura,et al. Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .
[85] S. Murad,et al. Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.
[86] C. Sotozono,et al. HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.
[87] P. Kwan,et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China , 2010, Epilepsy & Behavior.
[88] J. Roujeau,et al. Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis , 2010, The British journal of dermatology.
[89] G. Gambaro,et al. Identification of GDNF gene sequence variations in patients with medullary sponge kidney disease. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[90] S. Tiamkao,et al. Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.
[91] R. Hui,et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. , 2010, Pharmacogenomics.
[92] R. Cartotto,et al. What Are the Fluid Requirements in Toxic Epidermal Necrolysis? , 2010, Journal of burn care & research : official publication of the American Burn Association.
[93] L. Brochard,et al. Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Epidemiology, Risk Factors, and Predictive Value of Skin Cultures , 2010, Medicine.
[94] C. Joshi,et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.
[95] H. Shimizu,et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. , 2009, Annals of internal medicine.
[96] G. Gambaro,et al. The origin of nephrocalcinosis, Randall's plaque and renal stones: a cell biology viewpoint. , 2009, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[97] S. Tiamkao,et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.
[98] B. K. Park,et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. , 2009, Chemical research in toxicology.
[99] E. Gubinelli,et al. Toxic epidermal necrolysis successfully treated with etanercept , 2009, The Journal of dermatology.
[100] Yuan-Tsong Chen,et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.
[101] R. Abe. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. , 2008, Journal of dermatological science.
[102] K. Suphapeetiporn,et al. Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.
[103] C. Sotozono,et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.
[104] Howard L McLeod,et al. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.
[105] A. Trinchieri. Epidemiology of urolithiasis: an update. , 2008, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[106] A. Luke,et al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[107] A. Kołtan,et al. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. , 2008, Acta dermato-venereologica.
[108] S. Mallal,et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[109] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[110] L. Naldi,et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.
[111] Shui-Tein Chen,et al. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. , 2007, The Journal of allergy and clinical immunology.
[112] G. Curhan. Epidemiology of stone disease. , 2007, The Urologic clinics of North America.
[113] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[114] P. Kwan,et al. Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.
[115] G. Stingl,et al. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. , 2007, The Journal of investigative dermatology.
[116] M. Pirmohamed,et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. , 2006, Pharmacogenomics.
[117] S. Jee,et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.
[118] A. Trinchieri. Epidemiological trends in urolithiasis: impact on our health care systems , 2006, Urological Research.
[119] A. Trinchieri,et al. Effect of potential renal acid load of foods on urinary citrate excretion in calcium renal stone formers , 2006, Urological Research.
[120] N. Yawalkar,et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment , 2005 .
[121] C. Rubino,et al. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. , 2005, British journal of plastic surgery.
[122] G. Wilkinson,et al. Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.
[123] J. Cauley,et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men , 2005, Osteoporosis International.
[124] Yuan-Tsong Chen,et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[125] A. Roses,et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.
[126] J. Roujeau,et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. , 2004, The Journal of investigative dermatology.
[127] Martine Bagot,et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.
[128] T. Bellón,et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. , 2004, The Journal of allergy and clinical immunology.
[129] Yuan-Tsong Chen,et al. A marker for Stevens–Johnson syndrome , 2004 .
[130] I. James,et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[131] N. Abate,et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. , 2004, Kidney international.
[132] D. Metry,et al. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. , 2003, Pediatrics.
[133] W. Pichler,et al. Delayed Drug Hypersensitivity Reactions , 2003, Annals of Internal Medicine.
[134] R. S. Padilla,et al. Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study , 2003, Dermatology.
[135] P. Friedmann,et al. Mechanisms in cutaneous drug hypersensitivity reactions , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[136] J. Tschopp,et al. Intracellular Localization of Keratinocyte Fas Ligand Explains Lack of Cytolytic Activity under Physiological Conditions* , 2003, The Journal of Biological Chemistry.
[137] H. Shimizu,et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. , 2003, The American journal of pathology.
[138] R. Paterson,et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. , 2003, The Journal of clinical investigation.
[139] W. Pichler,et al. Modes of presentation of chemical neoantigens to the immune system. , 2002, Toxicology.
[140] W. Pichler. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept , 2002, Current opinion in allergy and clinical immunology.
[141] A. Karagianni,et al. Plasma exchange in patients with toxic epidermal necrolysis. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[142] Martine Bagot,et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. , 2002, The Journal of investigative dermatology.
[143] Clive E. Bowman,et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.
[144] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[145] A. Shetty,et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. , 2000, The Journal of rheumatology.
[146] J. Roujeau,et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.
[147] F. Cappuccio,et al. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. , 2000, Journal of nephrology.
[148] J. Roujeau,et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors , 2000, Clinical and experimental immunology.
[149] F. Sjöberg,et al. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? , 1999, Intensive Care Medicine.
[150] E. Rimm,et al. Nephrolithiasis and Risk of Hypertension , 1999 .
[151] J. Saffle,et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. , 1999, Journal of the American Academy of Dermatology.
[152] M Pirmohamed,et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity , 1999, British journal of pharmacology.
[153] W. Willett,et al. Nephrolithiasis and risk of hypertension in women. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[154] J. Tschopp,et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.
[155] C. Jost,et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[156] K. Takamori,et al. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[157] E. Padovan,et al. Molecular features of penicillin allergy. , 1998, The Journal of investigative dermatology.
[158] L. Jefferson,et al. Nutrition requirements in patients with toxic epidermal necrolysis. , 1997, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[159] D. Loannides,et al. Plasmapheresis in toxic epidermal necrolysis , 1997, International journal of dermatology.
[160] I. McInnes,et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis , 1997, Nature Medicine.
[161] R. Low,et al. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall's plaque formation. , 1996, The Journal of urology.
[162] R. Hiatt,et al. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. , 1996, American journal of epidemiology.
[163] J. Roujeau,et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis , 1996, The British journal of dermatology.
[164] A. H. Drummond,et al. Fas ligand in human serum , 1996, Nature Medicine.
[165] A. Mason,et al. Burn center care for patients with toxic epidermal necrolysis. , 1995, Journal of the American College of Surgeons.
[166] D. Kok,et al. Calcium oxalate nephrolithiasis, a free or fixed particle disease. , 1994, Kidney international.
[167] A. Vanderkelen,et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. , 1994, Archives of dermatology.
[168] O. Correia,et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. , 1993, Archives of dermatology.
[169] E. Alexopoulos,et al. Plasma Exchange (Pe) Treatment in Drug-Induced Toxic Epidermal Necrolysis (Ten) , 1991, The International journal of artificial organs.
[170] E. Topol,et al. Increased risk for abrupt closure during elective PTCA in the post-myocardial infarction period , 1991 .
[171] J. Roujeau,et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. , 1987, Archives of dermatology.
[172] G. Shires,et al. Improved Burn Center Survival of Patients with Toxic Epidermal Necrolysis Managed without Corticosteroids , 1986, Annals of surgery.
[173] B. Czarnetzki,et al. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. , 1985, Archives of dermatology.
[174] C. M. Ginsburg. Stevens-Johnson syndrome in children. , 1982, Pediatric infectious disease.
[175] W. Robertson,et al. Factors influencing the crystallisation of calcium oxalate in urine - critique , 1981 .
[176] M. Peacock,et al. Risk factors in calcium stone disease of the urinary tract. , 1978, British journal of urology.
[177] A. Randall. THE ORIGIN AND GROWTH OF RENAL CALCULI , 1937, Annals of surgery.
[178] S. Mallal,et al. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. , 2018, The journal of allergy and clinical immunology. In practice.
[179] S. Fook-Chong,et al. Cyclosporine treatment for Stevens‐Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center , 2017, Journal of the American Academy of Dermatology.
[180] M. A. Moreno Hidalgo,et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)‐induced SJS/TEN are different from those found for the same AED‐induced DRESS in the Spanish population , 2017, Pharmacological research.
[181] Piyush Kumar,et al. Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality. , 2016, Dermatology online journal.
[182] Ferraro Pietro Manuel,et al. Randall’s plaques, plugs and the clinical workup of the renal stone patient , 2014, Urolithiasis.
[183] D. Longo,et al. Necroptosis. , 2014, The New England journal of medicine.
[184] C. Serrano-Reyes,et al. Toxic epidermal necrolysis successfully treated with infliximab. , 2013, Journal of investigational allergology & clinical immunology.
[185] O. Faye,et al. Treatment of Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins (IVIg) , 2012, Drugs.
[186] M. Mockenhaupt,et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.
[187] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[188] M. Jonkman,et al. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2007, Acta dermato-venereologica.
[189] W. Pichler,et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. , 2006, Allergology international : official journal of the Japanese Society of Allergology.
[190] O. Faye,et al. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. , 2005, Drugs.
[191] R. Gamelli,et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? , 2004, The Journal of burn care & rehabilitation.
[192] J. Hawk,et al. Rook's Textbook of Dermatology. , 2004 .
[193] J. Roujeau,et al. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. , 2003, Archives of dermatology.
[194] F. Muldowney. Prevention of recurrent stones in idiopathic hypercalciuria. , 2002, The New England journal of medicine.
[195] J. Roujeau,et al. Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. , 2002, Archives of dermatology.
[196] H. Tiselius. Metabolic evaluation of patients with stone disease. , 1997, Urologia internationalis.
[197] T. Meschi,et al. URINARY VOLUME, WATER AND RECURRENCES IN IDIOPATHIC STUDY CALCIUM NEPHROLITHIASIS: A &YEAR RANDOMIZED PROSPECTIVE , 1996 .
[198] R. Stern,et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.